RD-14

N/A

Report date: 2025/02/11 17:16:34

Base Information

Drug NameRD-14

Drug Alias NameRD-14RD-14-01CTE001RD14-01

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionWnt signalling pathway modulatorsInactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists

TargetsInactive tyrosine-protein kinase transmembrane receptor ROR1

Therapy Area/IndicationsOvarian NeoplasmsBreast NeoplasmsLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaClinical

Originator CompaniesNanjing Bioheng Biotech Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesNanjing Bioheng Biotech Co Ltd

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsBreast NeoplasmsLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A